M&A in the Biotech sector rose by 25 per cent in the third quarter of 2016 compared to the two previous quarters, but is still down in activity seen in 2015. This activity was driven by small and medium deals but also the biggest deal of the year so far; German drug manufacturer Bayer’s takeover of the US agricultural seed producer, Monsanto, for $66 billion.
READ MORE >>Archives
Focus on Biotech M&A
Posted on October 7, 2016 By
Benchmark International in
Bayer +
Germany +
mergers +
US +
Abbot Laboratories +
Acquisition +
Acquisitions +
Baxalta +
Biogen +
Biotech +
Biotechs +
Blog +
Gilead Sciences +
Ionis Pharmaceuticals +
Merck and Allergan +
Mergers and Acquisitions +
Monsanto +
RNA +
Sage +
Sage Products +
Stryker Corp